Figure 1.

STS66 reduces NKCC1-mediated Rb⁺ influx in cultured glioma cells in a dose-dependent manner. (A) Experimental protocol. (B) Total Rb⁺ influx. GL26 or SB28-GFP cells were exposed to either isotonic (310 mOsm) or hypertonic (400 mOsm) solutions containing different concentrations of bumetanide (BMT; 0, 10, 20, 40, and 60 μM) or STS66 (0, 10, 20, 40, and 60 μM). Rb⁺ influx into cells under above conditions was assayed and determined using ICR 8000. (C) BMT- or STS66-inhibited Rb⁺ influx (NKCC1 activity). Data are means ± SEM (n = 3), ^*p < 0.05, ^**p < 0.01, ^***p < 0.001, ^****p < 0.0001.